Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Obinutuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Prednisone (Primary) ; Venetoclax (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 20 Jul 2023 Planned End Date changed from 15 Jul 2028 to 15 Jul 2029.
- 20 Jul 2023 Planned primary completion date changed from 15 Jul 2023 to 15 Jul 2024.
- 08 May 2023 Planned number of patients changed from 32 to 55.